References
- Abraham I, Lee KKC, Gregg M. Journal of medical economics in review: the best of 2021. J Med Econ. 2022;25(1):282–286.
- Journal of Medical Economics: Aims and scope [Internet]. London (UK): Informa UK Limited; [cited 2023 Jan 25]. Available from: https://www.tandfonline.com/action/journalInformation?show=aimsScope&journalCode=ijme20
- Kirson N, Swallow E, Lu J, et al. The societal economic value of COVID-19 vaccines in the United States. J Med Econ. 2022;25(1):119–128.
- Kilcoyne A, Jordan E, Zhou A, et al. Clinical and economic benefits of lenzilumab plus standard of care compared with standard of care alone for the treatment of hospitalized patients with COVID-19 in the United States from the hospital perspective. J Med Econ. 2022;25(1):160–171.
- Aguiar-Ibáñez R, Hardern C, van Hees F, et al. Cost-effectiveness of pembrolizumab for the first-line treatment of patients with unresectable or metastatic MSI-H/dMMR colorectal cancer in the United States. J Med Econ. 2022;25(1):469–480.
- Menzies-Gow A, Steenkamp J, Singh S, et al. Tezepelumab compared with other biologics for the treatment of severe asthma: a systematic review and indirect treatment comparison. J Med Econ. 2022;25(1):679–690.
- Di Fusco M, Marczell K, Deger KA, et al. Public health impact of the Pfizer-BioNTech COVID-19 vaccine (BNT162b2) in the first year of rollout in the United States. J Med Econ. 2022;25(1):605–617.
- Di Fusco M, Shea KM, Lin J, et al. Health outcomes and economic burden of hospitalized COVID-19 patients in the United States. J Med Econ. 2021;24(1):308–317.
- Schein J, Adler LA, Childress A, et al. Economic burden of attention-deficit/hyperactivity disorder among children and adolescents in the United States: a societal perspective. J Med Econ. 2022;25(1):193–205.
- Graham CN, Watson C, Barlev A, et al. Mean lifetime survival estimates following solid organ transplantation in the US and UK. J Med Econ. 2022;25(1):230–237.
- Rautenberg TA, Downes M, Huy Tuan Kiet P, et al. Evaluating the cost utility of racecadotril in addition to oral rehydration solution versus oral rehydration solution alone for children with acute watery diarrhea in four low Middle-income countries: Egypt, Morocco, Philippines and Vietnam. J Med Econ. 2022;25(1):274–281.
- Cooper M, Smith S, Williams T, et al. How accurate are the longer-term projections of overall survival for cancer immunotherapy for standard versus more flexible parametric extrapolation methods? J Med Econ. 2022;25(1):260–273.
- Rubin JL, Lopez A, Booth J, et al. Limitations of standard cost-effectiveness methods for health technology assessment of treatments for rare, chronic diseases: a case study of treatment for cystic fibrosis. J Med Econ. 2022;25(1):783–791.
- van de Wetering G, Ignacio T, Dhanda D, et al. Modification of treatment-sequence model with a customizable number of treatments to better reflect contemporary and future clinical practice in moderate to severe psoriasis. J Med Econ. 2022;25(1):421–427.
- Husereau D, Drummond M, Augustovski F, et al. Consolidated health economic evaluation reporting standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. J Med Econ. 2022;25(1):1–7.
- Jakovljevic M, Jie Tan C, Chaiyakunapruk N, et al. Global article collection: essential reads from around the world. J Med Econ. 2022;25(1):864–869.